JP2022518392A5 - - Google Patents
Info
- Publication number
- JP2022518392A5 JP2022518392A5 JP2021540103A JP2021540103A JP2022518392A5 JP 2022518392 A5 JP2022518392 A5 JP 2022518392A5 JP 2021540103 A JP2021540103 A JP 2021540103A JP 2021540103 A JP2021540103 A JP 2021540103A JP 2022518392 A5 JP2022518392 A5 JP 2022518392A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- vhh
- molecule
- vhh molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19305031 | 2019-01-09 | ||
| EP19305031.7 | 2019-01-09 | ||
| PCT/EP2020/050318 WO2020144233A1 (en) | 2019-01-09 | 2020-01-08 | Transferrin receptor-binding molecules, conjugates thereof and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518392A JP2022518392A (ja) | 2022-03-15 |
| JP2022518392A5 true JP2022518392A5 (cg-RX-API-DMAC7.html) | 2022-12-19 |
| JP7599425B2 JP7599425B2 (ja) | 2024-12-13 |
Family
ID=65236972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540103A Active JP7599425B2 (ja) | 2019-01-09 | 2020-01-08 | トランスフェリン受容体結合分子、そのコンジュゲート、及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12152317B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3908608A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7599425B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113474369B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020206593B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021013559A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3124790A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191893A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020144233A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| JP7652807B2 (ja) * | 2020-06-24 | 2025-03-27 | サプリーム テクノロジーズ,ベー.フェー. | 単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用 |
| CA3202539A1 (en) * | 2020-12-02 | 2022-06-09 | University Health Network | Methods and uses for ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies |
| MX2023015520A (es) * | 2021-07-01 | 2024-01-22 | Denali Therapeutics Inc | Conjugados de oligonucleotidos dirigidos al receptor de transferrina. |
| TW202330591A (zh) * | 2021-11-19 | 2023-08-01 | 日商Jcr製藥股份有限公司 | 人類運鐵蛋白受體親和性肽 |
| JP7889887B2 (ja) * | 2021-12-02 | 2026-07-14 | リンノ ファーマシューティカルズ インコーポレイテッド | トランスフェリン結合抗体及びその使用 |
| US11939391B2 (en) * | 2021-12-06 | 2024-03-26 | MedAbome, Inc. | Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment |
| US20250066449A1 (en) * | 2021-12-31 | 2025-02-27 | Imnewrun, Inc. | Blood-brain barrier permeable fusion protein and uses thereof |
| EP4504950A1 (en) | 2022-04-01 | 2025-02-12 | Takeda Pharmaceutical Company Limited | Gene therapy for diseases with cns manifestations |
| CN119213030A (zh) * | 2022-05-16 | 2024-12-27 | 戴纳立制药公司 | 转铁蛋白受体结合结构域和包含其的蛋白 |
| CN120659627A (zh) * | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法 |
| US20260116990A1 (en) | 2022-11-23 | 2026-04-30 | Key2Brain Ab | Vhh antibodies and uses thereof |
| EP4622668A1 (en) | 2022-11-23 | 2025-10-01 | Key2Brain AB | Vhh antibodies and uses thereof |
| KR20250114322A (ko) * | 2022-12-02 | 2025-07-29 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-tfr1 항체 및 이의 용도 |
| TW202436352A (zh) * | 2023-02-07 | 2024-09-16 | 日商Jcr製藥股份有限公司 | 人類運鐵蛋白受體親和性肽 |
| CN116179607A (zh) * | 2023-03-27 | 2023-05-30 | 迦进生物医药(上海)有限公司 | 一种human TfR2高表达的稳转细胞株及其构建方法和应用 |
| CN116121306A (zh) * | 2023-03-27 | 2023-05-16 | 迦进生物医药(上海)有限公司 | 一种human TfR1高表达的稳转细胞株及其构建方法和应用 |
| JP2026519919A (ja) | 2023-04-03 | 2026-06-19 | ブイアイビー ブイゼットダブリュ | 血液脳関門通過抗体 |
| EP4480965A1 (en) | 2023-06-22 | 2024-12-25 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases |
| CN121969643A (zh) | 2023-06-22 | 2026-05-01 | 维克塔-霍洛斯公司 | 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗神经系统疾病的用途 |
| EP4480964A1 (en) | 2023-06-22 | 2024-12-25 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases |
| WO2024261332A2 (en) | 2023-06-22 | 2024-12-26 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases |
| CN121773136A (zh) * | 2023-07-04 | 2026-03-31 | 北京星奇原生物科技有限公司 | 抗-TfR1抗体及其用途 |
| AU2024329222A1 (en) | 2023-08-18 | 2026-02-12 | Eli Lilly And Company | Engineered transferrin receptor binding peptides as well as methods of making and using the same |
| US20250064958A1 (en) * | 2023-08-22 | 2025-02-27 | Eli Lilly And Company | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS |
| WO2025194170A1 (en) * | 2024-03-15 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of immune-related membrane proteins |
| WO2025194171A1 (en) * | 2024-03-15 | 2025-09-18 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors |
| WO2025207959A1 (en) * | 2024-03-27 | 2025-10-02 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| TW202602933A (zh) * | 2024-03-28 | 2026-01-16 | 美商健臻公司 | 與轉鐵蛋白受體1的特異性表位結合的多肽 |
| WO2025226642A1 (en) | 2024-04-25 | 2025-10-30 | Eli Lilly And Company | Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same |
| WO2026142988A1 (en) * | 2024-12-24 | 2026-07-02 | Dana-Farber Cancer Institute, Inc. | Receptor-mediated endocytosis for targeted internalization of c-c chemokine receptor 6 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP2008666A1 (en) * | 2007-06-29 | 2008-12-31 | Institut Pasteur | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications |
| AU2008322523B2 (en) | 2007-11-16 | 2013-10-10 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| FR2937322B1 (fr) | 2008-10-22 | 2013-02-22 | Vect Horus | Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues |
| FR2959229B1 (fr) | 2010-04-21 | 2013-01-18 | Vect Horus | Derives peptidiques, leur preparation et leurs utilisations |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| WO2013177062A2 (en) | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| DK2951201T3 (en) * | 2013-01-30 | 2018-01-08 | Vib Vzw | Novel chimeric polypeptides for screening and drug detection purposes |
| EP2899208A1 (en) * | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| EA035517B1 (ru) * | 2014-03-06 | 2020-06-29 | Нэшнл Рисеч Каунсил Оф Канада | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения |
| CA2967830A1 (en) | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | Tfr selective binding compounds and related methods |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| CA3033082A1 (en) * | 2016-08-06 | 2018-02-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
-
2020
- 2020-01-08 EP EP20700450.8A patent/EP3908608A1/en active Pending
- 2020-01-08 JP JP2021540103A patent/JP7599425B2/ja active Active
- 2020-01-08 CA CA3124790A patent/CA3124790A1/en active Pending
- 2020-01-08 EA EA202191893A patent/EA202191893A1/ru unknown
- 2020-01-08 US US17/421,412 patent/US12152317B2/en active Active
- 2020-01-08 BR BR112021013559-6A patent/BR112021013559A2/pt unknown
- 2020-01-08 WO PCT/EP2020/050318 patent/WO2020144233A1/en not_active Ceased
- 2020-01-08 CN CN202080008202.4A patent/CN113474369B/zh active Active
- 2020-01-08 AU AU2020206593A patent/AU2020206593B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7412521B2 (ja) | Cd47に対するヒト化及びキメラモノクローナル抗体 | |
| CN104105708B (zh) | PDGF受体β结合多肽 | |
| EP2501721B1 (en) | Multivalent antibodies comprising fab-dsfv | |
| AU2016304764C1 (en) | Antigen binding constructs to target molecules | |
| EP2523972B1 (en) | Threevalent antibodies | |
| CN106459216B (zh) | 多特异性抗体构建体 | |
| EP2475682B1 (en) | Multivalent antibodies | |
| JP7360720B2 (ja) | 抗pd―l1抗体およびその用途 | |
| US10472426B2 (en) | Disulfide stabilized DVD-Ig molecules | |
| JP2015509097A5 (cg-RX-API-DMAC7.html) | ||
| KR20150093744A (ko) | Bcma 항원 결합 단백질 | |
| KR20240107202A (ko) | 항-트랜스페린 수용체 항체 및 이의 용도 | |
| JP2022509372A5 (cg-RX-API-DMAC7.html) | ||
| WO2011061246A2 (en) | Multivalent antibodies | |
| WO2021207433A2 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| KR20210071987A (ko) | 항-cd79 항체 및 이들의 용도 | |
| JP2009529915A5 (cg-RX-API-DMAC7.html) | ||
| CN114652853A (zh) | 抗il-4r抗体-药物偶联物及医药用途 | |
| WO2024022438A1 (zh) | 一种抗rbd抗体及其用途 | |
| US11028132B1 (en) | Half-life optimized linker composition | |
| US12161889B2 (en) | Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB | |
| CN121263442A (zh) | 抗il1rap抗体 | |
| WO2023071953A1 (zh) | 抗cd26抗体及其应用 | |
| WO2022156670A1 (en) | Multispecific antibodies against sars-cov-2 and methods of use thereof | |
| TW202446418A (zh) | 使用抗群落刺激因子1受體抗體治療慢性移植物抗宿主病相關閉塞性細支氣管炎症候群之方法 |